VRTX – Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals IncorporVRTX
$484.24Name : Vertex Pharmaceuticals Incorpor
Sector : Healthcare
Industry: Biotechnology
Mark. Cap: $124,347,990,016.00
EPSttm : -2.08
Vertex Pharmaceuticals Incorpor
$484.24
0.81%$3.91Float Short %
1.78
Margin Of Safety %
Put/Call OI Ratio
0.65
EPS Next Q Diff
0.36
EPS Last/This Y
EPS This/Next Y
2.27
Price
484.3
Target Price
506.74
Analyst Recom
1.94
Performance Q
3.69
Relative Volume
0.87
Beta
0.42
Ticker: VRTX
of 1
| Date | Symbol | Last | P/C OI | P/C Vol | Total OI |
|---|---|---|---|---|---|
| 2025-01-23 | VRTX | 439.78 | 0.81 | 2.30 | 31751 |
| 2025-01-24 | VRTX | 439.7 | 0.91 | 0.67 | 33859 |
| 2025-01-27 | VRTX | 443.88 | 0.83 | 1.64 | 31576 |
| 2025-01-28 | VRTX | 440.67 | 0.86 | 1.62 | 32608 |
| 2025-01-29 | VRTX | 441.55 | 0.88 | 1.04 | 33189 |
| 2025-01-30 | VRTX | 438.5 | 0.87 | 1.32 | 33761 |
| 2025-01-31 | VRTX | 461.79 | 0.87 | 0.36 | 34858 |
| 2025-02-03 | VRTX | 470.17 | 0.64 | 0.29 | 34731 |
| 2025-02-04 | VRTX | 483.79 | 0.65 | 0.31 | 35952 |
| 2025-02-05 | VRTX | 488.43 | 0.64 | 0.34 | 38289 |
| 2025-02-06 | VRTX | 481 | 0.65 | 0.34 | 39155 |
| 2025-02-07 | VRTX | 469.09 | 0.67 | 0.71 | 39844 |
| 2025-02-10 | VRTX | 478.11 | 0.67 | 0.59 | 37041 |
| 2025-02-11 | VRTX | 454.99 | 0.68 | 0.65 | 44224 |
| 2025-02-12 | VRTX | 453.31 | 0.69 | 0.91 | 45856 |
| 2025-02-13 | VRTX | 462.59 | 0.68 | 0.71 | 46661 |
| 2025-02-14 | VRTX | 459.1 | 0.67 | 0.91 | 46554 |
| 2025-02-18 | VRTX | 462.11 | 0.66 | 0.62 | 38121 |
| 2025-02-19 | VRTX | 471.81 | 0.66 | 0.46 | 38456 |
| 2025-02-20 | VRTX | 480.43 | 0.65 | 0.16 | 38936 |
| 2025-02-21 | VRTX | 484.53 | 0.65 | 0.15 | 39381 |
| Date | Symbol | Last | P/C OI | P/C Vol | Total OI |
Current Page1 of 1
of 1
| Date | Ticker | Price | Current Quarter Growth Estimate | EBIT Estimation | Average EPS Estimate Current Year |
|---|---|---|---|---|---|
| 2025-01-23 | VRTX | 439.73 | -2.3 | 5417.2 | 0.54 |
| 2025-01-24 | VRTX | 439.71 | -2.3 | 5246.5 | 0.54 |
| 2025-01-27 | VRTX | 443.72 | -2.3 | 5312.1 | 0.54 |
| 2025-01-28 | VRTX | 440.73 | -2.3 | 5216.9 | 0.54 |
| 2025-01-29 | VRTX | 441.42 | -2.3 | 5267.8 | 0.54 |
| 2025-01-30 | VRTX | 438.40 | -4.0 | 5217.0 | 0.54 |
| 2025-01-31 | VRTX | 461.67 | -4.2 | 5553.4 | 0.54 |
| 2025-02-03 | VRTX | 470.37 | -4.0 | 5354.8 | 0.54 |
| 2025-02-04 | VRTX | 482.33 | -4.3 | 5392.8 | 0.54 |
| 2025-02-05 | VRTX | 488.73 | -4.3 | 5317.8 | 0.54 |
| 2025-02-06 | VRTX | 480.99 | -4.3 | 5158.1 | 0.54 |
| 2025-02-07 | VRTX | 469.31 | -4.3 | 5143.9 | 0.54 |
| 2025-02-10 | VRTX | 469.97 | -4.3 | 5295.1 | 0.54 |
| 2025-02-11 | VRTX | 455.21 | -4.3 | 5104.4 | 0.54 |
| 2025-02-12 | VRTX | 453.03 | -4.3 | 5259.1 | 0.54 |
| 2025-02-13 | VRTX | 462.58 | -4.3 | 5407.2 | 18.18 |
| 2025-02-14 | VRTX | 459.00 | -4.3 | 5237.6 | 18.13 |
| 2025-02-18 | VRTX | 462.29 | -9.6 | 5347.5 | 18.13 |
| 2025-02-19 | VRTX | 471.76 | -9.6 | 5427.0 | 18.13 |
| 2025-02-20 | VRTX | 480.49 | -9.5 | 5224.6 | 18.11 |
| 2025-02-21 | VRTX | 484.30 | -9.5 | 5167.1 | 18.11 |
| Date | Ticker | Price | Current Quarter Growth Estimate | EBIT Estimation | Average EPS Estimate Current Year |
Current Page1 of 1
of 1
| Date | Ticker | Insider Transactions | Institutional Transactions | Float Short |
|---|---|---|---|---|
| 2025-01-23 | VRTX | -9.54 | -0.09 | 1.54 |
| 2025-01-24 | VRTX | -9.54 | -0.09 | 1.54 |
| 2025-01-27 | VRTX | -7.17 | -0.23 | 1.54 |
| 2025-01-28 | VRTX | -6.90 | -0.23 | 1.71 |
| 2025-01-29 | VRTX | -6.90 | -0.23 | 1.71 |
| 2025-01-30 | VRTX | -6.90 | -0.23 | 1.71 |
| 2025-01-31 | VRTX | -6.90 | -0.23 | 1.71 |
| 2025-02-03 | VRTX | -4.06 | -0.37 | 1.71 |
| 2025-02-04 | VRTX | -3.77 | -0.37 | 1.71 |
| 2025-02-05 | VRTX | -3.91 | -0.37 | 1.71 |
| 2025-02-06 | VRTX | -3.91 | -0.37 | 1.71 |
| 2025-02-07 | VRTX | -3.91 | -0.37 | 1.71 |
| 2025-02-10 | VRTX | -3.59 | -0.52 | 1.71 |
| 2025-02-11 | VRTX | -1.83 | -0.52 | 1.72 |
| 2025-02-12 | VRTX | -1.83 | -0.52 | 1.78 |
| 2025-02-13 | VRTX | -2.23 | -0.52 | 1.78 |
| 2025-02-14 | VRTX | -3.27 | -0.52 | 1.78 |
| 2025-02-18 | VRTX | -3.28 | -0.96 | 1.78 |
| 2025-02-19 | VRTX | -3.55 | -0.96 | 1.78 |
| 2025-02-20 | VRTX | -3.55 | -0.96 | 1.78 |
| 2025-02-21 | VRTX | -3.36 | -0.96 | 1.78 |
| Date | Ticker | Insider Transactions | Institutional Transactions | Float Short |
Current Page1 of 1
Last Quarter Act. EPS
3.98
Avg. EPS Est. Current Quarter
4.31
Avg. EPS Est. Next Quarter
4.34
Insider Transactions
-3.36
Institutional Transactions
-0.96
Beta
0.42
Average Sales Estimate Current Quarter
2847
Average Sales Estimate Next Quarter
2910
Fair Value
Quality Score
70
Growth Score
73
Sentiment Score
98
Actual DrawDown %
6.8
Max Drawdown 5-Year %
-41.6
Target Price
506.74
P/E
Forward P/E
23.45
PEG
P/S
11.32
P/B
7.58
P/Free Cash Flow
EPS
-2.2
Average EPS Est. Cur. Y
18.11
EPS Next Y. (Est.)
20.38
Target Price Estimates Raised
Target Price Estimates Lowered
Profit Margin
-4.88
Relative Volume
0.87
Return on Equity vs Sector %
-22.5
Return on Equity vs Industry %
-6.9
EPS 1 7Days Diff
EPS 1 30Days Diff
-0.56
EBIT Estimation
5167.1
Vertex Pharmaceuticals IncorporSector: Healthcare
Industry: Biotechnology
Employees: 6100
Vertex Pharmaceuticals Incorporated, a biotechnology company, engages in developing and commercializing therapies for treating cystic fibrosis (CF). It markets TRIKAFTA/KAFTRIO for people with CF with at least one F508del mutation for 2 years of age and older; ALYFTREK for the treatment for people with CF 6 years of age and older; SYMDEKO/SYMKEVI for treatment of patients with CF 6 years of age and older; ORKAMBI for CF patients 1 year or older; and KALYDECO for the treatment of patients with 1 month or older who have CF with ivacaftor. The company also develops CASGEVY for the treatment of sickle cell disease and transfusion-dependent beta thalassemia; JOURNAVX for the treatment of acute pain in adults; VX-522, a CFTR mRNA therapeutic designed to treat the underlying cause of CF, which is in Phase 1/2 clinical trial; inaxaplin for the treatment of APOL1-mediated kidney disease which is in single Phase 2; VX-880 and VX-264, treatment for Type 1 Diabetes; VX-670 for the treatment of myotonic dystrophy type 1; and VX-407, a small molecule corrector for the treatment of autosomal dominant polycystic kidney disease. Further, it sells the products to specialty pharmacy and specialty distributors in the United States, as well as retail pharmacies, hospitals, and clinics. Additionally, the company has collaborations with CRISPR Therapeutics AG.; Moderna, Inc.; and Entrada Therapeutics, Inc. Vertex Pharmaceuticals Incorporated was founded in 1989 and is headquartered in Boston, Massachusetts.
stock quote shares VRTX – Vertex Pharmaceuticals Incorporated Stock Price stock today
news today VRTX – Vertex Pharmaceuticals Incorporated stock forecast ,stock prediction 2023 2024 2025
marketwatch VRTX – Vertex Pharmaceuticals Incorporated yahoo finance google finance
stock history VRTX – Vertex Pharmaceuticals Incorporated invest stock market
stock prices VRTX premarket after hours
ticker VRTX fair value insiders trading